Summary. The direct oral anticoagulants (DOACs) are therapeutic alternatives to warfarin and other vitamin K antagonists (VKAs), and constitute the standard of care for many indications. VKAs constitute the conventional therapy for the treatment and secondary thromboprophylaxis of thrombotic antiphospholipid syndrome (APS), but are often problematic, owing to the variable sensitivity of thromboplastins to lupus anticoagulant. Thus, the International Normalized Ratio may not accurately reflect anticoagulation intensity, or be clinically effective. Definition of the current role of DOACs in the treatment of APS is based on limited clinical trial data and information from other sources, including manufacturers' data, case series or cohort studies, and expert consensus. The Rivaroxaban in Antiphospholipid Syndrome (RAPS) randomized controlled trial (RCT), which had a laboratory surrogate primary outcome measure, suggests that rivaroxaban has the potential to be an effective and convenient alternative to warfarin in thrombotic APS patients with a single venous thromboembolism event requiring standard-intensity anticoagulation. However, further studies, in particular to provide better long-term efficacy and safety data, are needed before it can be widely recommended. APS patients are clinically heterogeneous, with the risk of recurrent thrombosis and the intensity of anticoagulation being influenced by their clinical phenotype and risk profile. DOAC trials involving homogeneous thrombotic APS populations, with the antiphospholipid antibody status well defined, will help to optimize the appropriate treatment in APS patient subgroups. Ongoing and emerging DOAC RCTs should provide further information to guide the use of DOACs in APS patients. Optimal identification of APS patients is a key step in working towards improved therapeutic strategies in these individuals.
Introduction
Antiphospholipid syndrome (APS) manifests as thrombosis (arterial, venous, or microvascular) and/or obstetrical morbidity in association with persistent antiphospholipid antibodies (aPL), i.e. lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and/or anti-b 2 glycoprotein-1 antibodies (ab 2 GP1) [1] . Thrombotic APS is clinically heterogeneous, with thrombotic episodes ranging from mild to potentially life-threatening, refractory thrombosis despite adequate anticoagulation, and the rare catastrophic APS. Thrombotic events may be venous, arterial, or microvascular. APS mainly affects relatively young individuals. The median age at study entry in the Euro-Phospholipid Project of 1000 patients, > 70% of whom had stroke or venous thromboembolism (VTE), was 40 years (range 0-82 years) [2] . Among systemic lupus erythematosus (SLE) patients, 30-40% have aPL [3] , with estimates of the frequency with which APS occurs in patients with SLE ranging from 7% to 22% [4, 5] . SLE patients with APS are often difficult to manage, because of complex clinical problems [6] . Warfarin or other vitamin K antagonists (VKAs) constitute the conventional therapy for the treatment and secondary thromboprophylaxis of thrombotic APS [7] . However, treatment with VKAs is often problematic, as they have a slow onset of action of several days, a narrow therapeutic window, numerous drug and dietary interactions, and the potential for variation of action in the presence of alcohol, intercurrent illness, exercise, and smoking.
Patients require regular monitoring of the International Normalized Ratio (INR). The direct oral anticoagulants (DOACs) dabigatran, which is a direct thrombin inhibitor, and apixaban, edoxaban, and rivaroxaban, which are direct activated factor X (FXa) inhibitors, represent a major milestone in anticoagulation. They are therapeutic alternatives to VKAs and constitute the standard of care for many indications, as detailed in the summary of product characteristics (SPC) [8] [9] [10] [11] . DOACs, in contrast to VKAs, are prescribed at a fixed dose with a more predictable anticoagulant effect, and do not routinely require regular anticoagulant monitoring. They have a rapid onset of action, which generally obviates the need for bridging anticoagulation with low molecular weight heparin (LMWH) [9, 11] , are not affected by dietary changes and alcohol intake, and have fewer drug interactions than VKAs that affect anticoagulant intensity. These features should improve patients' quality of life. The SPCs for the licensed DOACs [8] [9] [10] [11] do not contain information regarding the use of DOACs in patients with APS. Definition of the current role of DOACs in the treatment of APS is based on limited clinical data and information from other sources, including manufacturers' data, case series or cohort studies, and expert consensus.
Warfarin and other VKAs for the treatment of APS
Approximately 10% of APS patients overall [2] and 30% of those who are triple aPL-positive, i.e. have LA, aCL and ab 2 GP1 [12] , have recurrent thrombotic events, arterial or venous, while receiving VKAs (at standard intensity, target INR of 2.5) at 5-year follow-up. The high thrombotic risk of triple aPL-positive patients is also observed in asymptomatic individuals, in whom the risk of thrombosis is significantly higher than in those with single aPL positivity. The annual rate of a first cardiovascular event is 5.3% in triple aPL-positive individuals (cumulative incidence of 37% at 10 years) versus 1.36% in single aPL-positive individuals versus~0.4% in the normal population [13] . A systematic review of 16 studies indicated that APS patients receiving anticoagulation have major bleeding rates of 0.57-10% per year [14] .
VTE
Retrospective studies have shown a high incidence of thrombosis recurrence in patients with aPL [15] [16] [17] . In these studies, 54% (80/147), 56% (39/70) and 38% (23/ 61) of patients had VTE. In the prospective Duration of Anticoagulation (DURAC) study on 412 patients with VTE, a single aCL-positive test result doubled the risk of recurrence in the first 6 months after cessation of warfarin: 29% (20/68) in patients with aCL and 14% (47/ 334) in patients without aCL (P = 0.0013), giving a risk ratio of 2.1 (95% confidence interval 1.3-3.3) [18] . Current recommendations on the duration of anticoagulation in individuals with VTE who have APS are extrapolated from studies in the general VTE population [19] [20] [21] . Although indefinite anticoagulation is suggested for APS patients with unprovoked VTE and temporary anticoagulation for those with a provoked VTE [19, 22] , there are no specific substantive data on the optimal duration of anticoagulation for APS patients with VTE. A pragmatic approach is to test for aPL in patients who have had a first unprovoked VTE, as aPL positivity strengthens the decision to apply indefinite anticoagulation. It also identifies women who require higher than standard prophylactic-dose anticoagulation with LMWH during pregnancy [23] [24] [25] , and who also require low-dose aspirin and monitoring for placental insufficiency [26] , the latter to guide optimal timing of delivery, reducing the risk of perinatal morbidity and mortality. Testing for aPL is recommended in patients with unprovoked VTE [19] ; however, aPL testing should also be considered in patients with provoked VTE, particularly if the provoking factor for VTE appears to be disproportionately mild.
Stroke and other arterial thrombosis APS patients with stroke also require identification, in contrast to non-APS stroke patients, in whom antiplatelet treatment is the standard of care. Anticoagulation is a rational treatment for patients with APS and stroke, transient ischemic attack, or other ischemic brain manifestations, as it can lead to the resolution of in situ arterial thrombosis or prevent cardioembolic events. UK national clinical guidelines for stroke recommend aPL testing in individuals aged < 50 years [27] . There are limited data to guide the optimal anticoagulation intensity in APS patients with stroke or other arterial thrombosis. Ruiz-Irastorza et al. [14] reviewed 16 studies (four randomized controlled trials [RCTs] and 12 prospective or retrospective cohort studies) on secondary thromboprophylaxis in patients with aPL. Of 180 thrombotic events reported, 104 (57%) occurred when patients were not taking any anticoagulant or antiplatelet agent. Only seven of 49 recurrences (27%) occurred in patients taking warfarin when the INR was > 3.0; of these, in the five cases in which the type of thrombosis was specified, four were arterial and one was venous.
Three prospective studies have addressed the key issue of the optimal antithrombotic treatment for stroke patients with aPL; however, these have major limitations. Two RCTs on standard versus high-intensity warfarin in patients with thrombotic APS, reported by Crowther et al. [28] and Finazzi et al. [29] , concluded that the optimal target INR for venous and/or arterial thromboembolism, including stroke, in APS patients is 2.5 (range 2.0-3.0) (standard intensity) rather than 3.5 (range 3.0-4.0) (high intensity). However, patients with a history of recurrent thrombosis while receiving therapeutic anticoagulation or with arterial thrombosis were poorly represented in both studies, with the latter constituting 24% and 32%, respectively (62 of 223 patients across both studies). Notably, six of eight recurrent thrombotic events in the study of Crowther et al. [28] occurred while the INR was < 3.0 (5/6) or while the individuals were not receiving warfarin (1/6). The study of Finazzi et al. did not detail the INR at the time of thrombosis [29] . The Antiphospholipid Antibodies and Stroke Study (APASS) [30] , which was a prospective cohort study within the Warfarin vs. Aspirin Recurrent Stroke Study (WARSS), reported no benefit of warfarin anticoagulation (target INR of 1.4-2.8) over aspirin (325 mg daily) in stroke prevention. However, the laboratory criteria for aPL were not compliant with the international consensus criteria for APS diagnosis [30] .
The lack of robust data on the optimal anticoagulant intensity in ischemic stroke patients with APS is reflected in national and international guidelines. British Society for Haematology [19] and American College of Chest Physicians [31] guidelines on APS-associated ischemic stroke include warfarin (or another VKA) at a target INR of 2.5 (range 2.0-3.0). The Task Force at the 13th International Congress on aPL recommended that patients with definite APS and arterial thrombosis should be treated with warfarin at an INR of > 3.0 or combined antiplatelet-anticoagulant (target INR of 2.5) therapy [21] . This suggestion was a non-graded recommendation, owing to a lack of consensus within the Task Force. Many physicians treating APS patients use high-intensity warfarin (target INR of 3.5; range 3.0-4.0) for APS patients with ischemic stroke or other arterial thrombosis.
Laboratory issues in APS patients receiving VKAs or DOACs

Laboratory monitoring of anticoagulation in patients receiving warfarin
VKAs can be problematic in APS patients because of variable sensitivity of thromboplastins to LA [32, 33] . A multicenter study indicated that LA interference with the INR measured with the majority of commercial thromboplastins is insufficient to cause concern if insensitive thromboplastins, properly calibrated to assign them an instrument-specific International Sensitivity Index, are used. The investigators suggested that new thromboplastins, especially those made of relipidated recombinant human tissue factor (TF), should be checked to ensure that they are insensitive to the effects of aPL before being used to monitor oral anticoagulant treatment in APS patients [33] . These procedures are generally routine in specialist centers, but may not be available elsewhere. Thus, the INR might not accurately reflect anticoagulation intensity and, as a result, could be associated with potential thrombotic or bleeding complications. Amidolytic factor X assays, as an LA-independent measure of anticoagulation intensity, may be useful in such cases, although this is rarely practicable [32, 34] . The variable sensitivity of thromboplastins to LA may also be associated with instability of the INR, necessitating frequent anticoagulant monitoring, causing inconvenience to the patient, adversely impacting on quality of life, and increasing costs. Warfarin also interacts with many other drugs, altering the INR and complicating the treatment of APS patients with other disorders, including SLE.
Testing for aPL
LA testing in patients receiving VKAs is addressed in national and international guidelines [19, 35] . Tests for LA detection should include screening, mixing and confirmation steps performed with at least two different methodologies, with only one result required to be positive [19, 35] . Many studies have reported DOAC interference with tests for LA, leading to false-positive and unreliable results [36] [37] [38] [39] . Dabigatran and apixaban interfere with both activated partial thromboplastin time (aPTT) based and dilute Russell viper venom time (dRVVT) based tests [40] [41] [42] [43] . False-positive test results for aPTT based tests, silica clotting time tests and dRVVT have also been reported for rivaroxaban, particularly at peak plasma levels [36, 41, [44] [45] [46] . However, the Taipan venom time (TVT)/ecarin clotting time (ECT) ratio and Textarin time tests perform better, and are unaffected by rivaroxaban, irrespective of concentration. In thrombotic APS patients treated with rivaroxaban, the TVT/ECT ratio appears to be reliable even at peak therapeutic plasma levels, whereas the dRVVT may be acceptable at trough rivaroxaban plasma levels (> 18 h after the last dose of rivaroxaban), although a rivaroxaban anti-FXa assay should be performed in parallel to ensure that the result is not a false-positive [36, 43, 46] . No interference has been reported by any DOACs on solid-phase assays or ELISAs for ab 2 GPI or aCL [42, 44, 46] .
Thrombin generation (TG) and DOACs
TG, assessed by calibrated automated thrombography, represents a global dynamic assay that measures the overall ability of plasma to form thrombin after initiation of coagulation by using a thrombin-sensitive fluorogenic substrate. The TG curve, quantified in terms of the lag time, time to peak TG, peak TG, and endogenous thrombin potential (ETP), the area under the TG curve [47] , is informative with regard to APS status and LA detection [48, 49] . TG can be used to assess the effects of anticoagulants in platelet-poor plasma (PPP) and platelet-rich plasma (PRP), and in both APS and non-APS patients [34, 50, 51, 52] . Rivaroxaban can downregulate and completely suppress TG in whole blood, PRP [53, 54] , and PPP [55, 56] , whereas dabigatran can significantly inhibit TF-induced TG in a concentration-dependent manner, but with weaker inhibitory effects than rivaroxaban [57] . Apixaban affects all TG parameters, with prolonged lag time, ETP, and peak TG (the latter showing greater reduction than the ETP) [58] . aPL might interfere with the anticoagulant action of DOACs; however, no effect with rivaroxaban was observed in in vitro studies, which showed that aPL did not affect its anticoagulant action at peak or trough levels, on the basis of TG testing and anti-FXa levels [36] . This was predictable, as rivaroxaban is a small molecule with high specificity and affinity for its target [53, 59] .
Observational data on the use of DOACs in APS patients
Patients with aPL or APS were neither specifically included nor excluded from the phase 3 RCTs that demonstrated that DOACs are effective and safe as compared with warfarin for the treatment and secondary prevention of VTE after a first VTE event or the prevention of stroke or systemic embolism in patients with atrial fibrillation (AF) [8] [9] [10] [11] . APS is classified as a rare disease in the USA [60] . Systematic reviews suggest that aPL are present in 10% of patients with deep vein thrombosis (DVT) and in 14% of patients with stroke [61] , although this is not reflected in thrombotic APS patient numbers in clinical practice, suggesting probable underdiagnosis.
Data on APS derived from phase 3 RCTs of DOACs in the general population
Dabigatran
A post hoc analysis of pooled data on patients with aPL (LA and/or aCL) from the RE-COVER, RE-COVER II and RE-MEDY studies was undertaken [62] . aPL testing was not mandatory, but, when it was performed, the data were captured. Of 6822 patients in the pooled analysis, 151 (2.2%) had LA and/or aCL at baseline. In aPL-positive patients, there was no significant difference in VTE/ VTE-related deaths or major or clinically relevant nonmajor bleeding events between the two treatment arms. However, this study was heavily underpowered.
Apixaban
In the AMPLIFY RCT of apixaban 5 mg twice daily versus enoxaparin followed by a warfarin target INR of 2.5, relevant baseline risk factors for recurrent VTE included known thrombophilia: 74 (2.85%) patients in the apixaban arm, and 59 (2.2%) patients in the enoxaparin followed by warfarin arm. No separate analysis on the safety and efficacy in this specific patient population was performed [63] .
Edoxaban
The phase 3 ENGAGE-AF TIMI-48 AF study included one patient with aPL, one with APS, and approximately five with SLE or other autoimmune disease [64] .
Rivaroxaban
In the EINSTEIN phase 3 clinical trial program, adult patients with known thrombophilic conditions (antithrombin, protein C or protein S deficiency, FV or prothrombin gene mutations, or aPL) were not excluded [65, 66] . In the EINSTEIN DVT and pulmonary embolism (PE) pooled analysis, patients had a mean age of 57.0 AE 17.0 years. A total of 5.9% of patients in the rivaroxaban group and 5.7% in the enoxaparin/VKA group had a known thrombophilic disorder (6.2% versus 6.8% in EINSTEIN DVT [65] and 5.7% versus 5.0% in EINSTEIN PE [66] , respectively). The relative primary efficacy and principal safety outcomes across the prespecified subgroups (including the subgroup of patients with a known thrombophilic disorder) in the EINSTEIN DVT and the EINSTEIN PE studies were consistent with the observed overall effects.
Case series and cohort studies of DOACs in APS
Case reports, series and cohort studies have reported on DOAC use in APS patients, with approximately 200 cases having been reported. Several authors have reported case series and cohort studies describing thromboembolism recurrence in APS patients switched from warfarin to a DOAC [67] [68] [69] [70] [71] [72] (Table 1) . Other case series have reported that DOAC use in thrombotic APS was unassociated with recurrent thrombosis [73, 74] . Sciascia et al. reported a case series of 36 patients with APS and VTE requiring standard-intensity warfarin who were switched to rivaroxaban 20 mg once daily, and followed for a median of 10 months (range 6-24 months). None of these patients had recurrent thrombosis [73] . These data, with their inherent limitations, including selection bias, lack of a comparator arm, and, in some studies a retrospective design, suggest that recurrent thrombotic events in APS patients receiving DOACs mainly occur when DOACs are used for secondary prevention of APS-related arterial or microvascular thrombosis, indications for which DOACs are unlicensed, and for which many APS treaters use high-intensity anticoagulation [22] , or use anticoagulation in triple aPL-positive APS patients (Table 1) .
Rivaroxaban in Antiphospholipid Syndrome (RAPS) pilot feasibility study
The RAPS pilot feasibility study (ClinicalTrials.gov: NCT02116036) was a prospective cohort study on patients with confirmed APS and prior VTE, with or without prior arterial thrombosis, allocating them to receive rivaroxaban 20 mg daily. Patients were followed for thrombosis. Recruitment was closed on 30 September 2016, with a plan to follow all patients for 1 year. Eighty-one patients were identified, with the recruitment target being 150. The available information indicates that few complications, and no recurrent thromboses, occurred. One patient suffered unexplained hepatitis [7] . This study provides additional data on the efficacy and safety of DOACs in APS patients.
RCTs of DOACs in APS
A challenge in DOAC APS studies is ensuring sufficient statistical power. Trials with clinical outcomes are ideal; however, when APS trials with clinical outcomes have succeeded, the numbers have been relatively small, e.g. 334 patients in five RCTs on treatment for APS-associated recurrent miscarriage in the meta-analysis by Mak et al. [75] , and trials with larger recruitment targets have proved challenging [76, 77] . The appropriateness or otherwise of the use of surrogate markers in clinical trials was considered in an editorial review by Svennson et al., who, after supporting their use in fatal diseases such as amyotrophic lateral sclerosis, went on to say that they felt this approach was justified: 'in the case of very rare diseases, (where) validation of hard end points may take an unreasonable time to complete' [78] .
The characteristics and status of completed and recruiting RCTs of DOACs in thrombotic APS are summarized in Table 2 .
RAPS trial
The RAPS trial is the only completed RCT on DOAC use in APS patients. This phase 2/3 non-inferiority RCT compared rivaroxaban with warfarin (target INR of 2.5; range 2.0-3.0) for the treatment of patients with previous VTE [79] receiving standard-intensity warfarin for at least 3 months after the last VTE. Warfarin-treated APS patients with previous VTE, with or without SLE, were randomized 1 : 1 to warfarin or rivaroxaban, 20 mg once daily, stratified by center and SLE/non-SLE. Table 1 Case series and cohort studies in which thrombotic antiphospholipid syndrome patients treated with direct oral anticoagulants (DOACs) developed recurrent thrombosis Case series [67] Case series [68] Case series [69] Cohort [70] Cohort [71] Case series [72] No The primary outcome measure was percentage change in ETP in the TG assay from randomization to day 42, with treatment continued for 180 days and follow-up for 210 days. One hundred and sixteen patients were randomized, of whom 19% had SLE. When anticoagulation intensity was assessed by ETP alone, rivaroxaban was inferior to warfarin. However, peak TG was lower with rivaroxaban ( Fig. 1) . Warfarin affects all phases of TG equally, whereas rivaroxaban directly inhibits FXa through specific binding to its active site [53, 59] , and mainly affects the initiation and propagation of TG, leading to a delay in the formation of the prothrombinase complex [59] . Consequently, the TG curve becomes protracted, lengthening the lag time and time to peak TG [50, 52] , and leading to greater ETP than would be expected for the degree of anticoagulation [52] . The RAPS trial concluded that, taking into account the altered reaction kinetics with rivaroxaban, the overall thrombogram indicated no difference in thrombotic risk. This conclusion was supported by in vivo coagulation activation marker levels (thrombin-antithrombin complexes, prothrombin fragment 1 + 2, and D-dimer) being slightly raised in a few patients in both treatment groups. Furthermore, no new thrombotic events were seen during 6 months of treatment. No major bleeding episodes were noted. Clinically relevant and minor bleeding rates were similar in the two groups. Quality of life was significantly improved in patients receiving rivaroxaban.
The RAPS trial was not designed to confirm clinical efficacy and long-term safety. Rather, the trial was designed pragmatically with a laboratory surrogate outcome measure to assess the mechanism of action of the interventions in the two patient groups. Recurrent thrombosis in the APS population selected for the RAPS trial is rare, and a primary endpoint of recurrent thrombosis would necessitate several thousand patients and a follow-up period of several years, which is impractical. The trial had an intended selection bias, ensuring a clinically homogeneous study population with definite APS [1] . Patients who had VTE and developed recurrent VTE while taking standardintensity anticoagulation (i.e. needing higher-intensity anticoagulation) and those with arterial events were excluded. The proportion of triple aPL-positive patients included, 28%, was representative of VTE patients requiring standard-intensity anticoagulation in the investigators' APS population, and consistent with the proportion in APS patients suggested in a large multicenter study [2] . The conclusions from the RAPS trial were generally supported by independent expert comment [80] .
Exploratory post hoc analysis in the RAPS trial patients showed no significant interactions between the effects of rivaroxaban and LA positivity on TG. Coagulation proteases such as FXa can activate complement proteins. In a RAPS translational study, APS patients had significantly higher levels of complement activation markers at baseline and on day 42 than normal controls. Patients randomized to rivaroxaban showed a significant reduction in the levels of C3a, C5a, and terminal complement complex (SC5b-9), with levels of Bb fragment, a marker of alternative complement pathway activation, being unchanged. These results suggest that rivaroxaban may provide additional benefit to its anticoagulant effect in APS patients by limiting complement activation [81] . Table 2 Characteristics and status of completed and recruiting randomized controlled trials (RCTs) of direct oral anticoagulants in thrombotic antiphospholipid syndrome (APS) RAPS [79] TRAPS [7, 82] ASTRO-APS [7, 83] Chief 
Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS) trial
The objective of the TRAPS multicenter phase 3 RCT was to demonstrate non-inferiority of rivaroxaban 20 mg (15 mg in patients with moderate renal insufficiency) once daily versus warfarin (target INR of 2.5; range 2.0-3.0) with respect to cumulative incident thrombosis (arterial or venous) confirmed by imaging studies, major bleeding and death in triple aPL-positive APS patients. The trial planned to recruit 536 patients [7, 82] . However, it was terminated in January 2018 because of unbalance in the composite endpoint between arms.
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome (ASTRO-APS) trial
The ASTRO-APS RCT is comparing apixaban with warfarin (target INR of 2.5; range 2.0-3.0) for the secondary prevention of thromboembolism among patients with a history of APS and thrombosis [83] . The ASTRO-APS trial was originally designed to compare apixaban 2.5 mg or 5 mg twice daily with warfarin, by enrolling patients with a history of arterial or venous thromboses receiving indefinite anticoagulation. APS patients are categorized as having definite, likely or historical APS, so the ASTRO-APS trial may include patients who do not meet the International Consensus Criteria for APS diagnosis [1] . After accrual of the first 25 patients, a prespecified Data Safety Monitoring Board (DSMB) review recommended that the protocol be modified to apixaban 5 mg twice daily. In this context, patients with indications for long-term treatment with a VKA, such as aPL, were excluded from AMPLIFY-EXT, in which a dose of 2.5 mg twice daily was used [84] . After five more patients had been enrolled, a potential safety signal led to an ad hoc DSMB re-review, which recommended continuing the ASTRO-APS trial, as a phase 4 pilot interventional study, excluding patients with prior arterial thrombosis; and undertaking brain magnetic resonance imaging with stroke protocol for all otherwise eligible candidates to exclude prior silent stroke. The ASTRO-APS trial plans to enroll 200 patients [7, 83] .
Rivaroxaban for Stroke Patients with Antiphospholipid Syndrome (RISAPS) trial
The RISAPS open-label, phase 2/3 non-inferiority RCT (Chief Investigator H. Cohen), funded by Arthritis Research UK (reference: 21517), will assess the efficacy of rivaroxaban versus warfarin in adult patients with APS, with or without SLE, who have ischemic stroke or other ischemic brain manifestations.
Use of DOACs in APS patients in clinical practice
The RAPS trial suggests that rivaroxaban has the potential to be an effective and convenient alternative to warfarin in thrombotic APS patients with a single VTE event requiring standard-intensity anticoagulation [79] . Further studies, in particular to provide better long-term efficacy and safety data, are needed before it can be widely recommended. It is of note that the major phase 3 clinical trials that established the use of DOACs versus warfarin for the treatment and secondary prevention of VTE used warfarin at a target INR of 2.5 (range 2.0-3.0) as the comparator. The optimal intensity of DOACs in patients who experience recurrent VTE while receiving standard-intensity VKAs, in whom it is usual to switch to high-intensity VKAs (target INR of suggests that rivaroxaban might be useful in selected APS patients with single venous thrombosis requiring standard intensity anticoagulation; however, this needs to be confirmed with additional studies using clinical outcome measures' [7] . The case series and cohort studies on DOAC use in APS patients suggest that recurrent thrombotic events with standard-intensity DOACs in APS patients mainly occur when DOACs are used for secondary prevention of APS-related arterial or microvascular thrombosis [67] [68] [69] [70] [71] [72] , when DOACs are unlicensed [8] [9] [10] [11] . We believe that these patient groups should not be treated with DOACs until further trial data are available.
Practical clinical issues
The potential use of DOACs in APS patients requires considerations similar to those for their use in non-APS patients, including those with renal or hepatic impairment, the elderly, or those receiving potentially interacting drugs, in accordance with the DOAC SPCs [8] [9] [10] [11] . Drug interactions and the potential for gastrointestinal bleeding are of particular relevance in APS patients in whom an antiplatelet agent is considered in addition to anticoagulation, or in patients with SLE or other autoimmune diseases in whom other drugs may be considered, including non-steroidal anti-inflammatory drugs and steroids. Proton pump inhibitor cover is advisable. The optimal dosing strategy for DOACs in patients at extremes of body weight, i.e. > 120 kg or < 50 kg, has raised concern. Several studies, including a review of phase 1-3 studies of rivaroxaban [85] , measurement of rivaroxaban levels at various weight ranges [86] , and a pharmacokinetic study [87] , suggest that standard-dose rivaroxaban can be used safely in patients of all weights; however, further data are required. ISTH Scientific and Standardization Committee guidance recommends that DOACs should not be used for standard indications in obese patients, i.e. those weighing > 120 kg, but, if they are used, that drug-specific peak and trough levels should be checked. If the drug level is within the expected range, the DOAC can be continued; if not, it should be switched to a VKA [88] . The management of bleeding in patients receiving DOACs is addressed elsewhere [89] . Idarucizumab, an antibody fragment that binds to and neutralizes dabigatran, is licensed for rapid reversal of dabigatran [90] , and andexanet-alfa has been shown to be effective for reversal of FXa inhibitors [91] .
Although the use of warfarin has the advantage that its regular monitoring helps to determine the degree of patient adherence, its many complications drive the need to assess alternative therapies. The development of DOACs now provides such alternatives; however, good adherence to anticoagulation is essential, particularly as the risk of thrombosis is compounded by the short halflives of DOACs as compared with those of VKAs. A systematic review indicated that poor adherence to INR monitoring in patients receiving VKAs is a risk factor for recurrent thrombosis following a switch to a DOAC [92] , and such a switch is therefore probably best avoided when there is pre-existing poor adherence. Measurement of the DOAC concentration may be helpful in certain circumstances, including extremes of body weight and to confirm absorption; however, routine anticoagulant monitoring of DOAC levels is generally not practicable.
Women's health issues
There is a preponderance of women with APS (female/ male ratio of approximately 5 : 1), many of whom have both thrombotic and obstetrical APS [2] . Vaginal bleeding complications constitute a common complication of oral anticoagulation [93] , and appear to occur more often with direct oral FXa inhibitors than with VKAs [94] . BeyerWestendorf et al. reported vaginal bleeding events in 57 of 178 women of reproductive age in the Dresden DOAC registry, with recurrent bleeding occurring in 23%. Patients with anatomical abnormalities had more intense bleeding, and more of them needed surgical treatment [95] . A proactive approach, with gynecological input, is required. A temporary interruption or dose reduction of DOAC on days when bleeding is heaviest can be sufficient to prevent recurrent heavy menstrual bleeding (HMB). A levonorgestrel intrauterine system (LNG-IUS Mirena) is the most effective medical intervention for HMB [96] , and avoids the potential thrombogenic effects of oral hormonal preparations. Tranexamic acid is an effective alternative or adjunct [96] . A switch to split-dose LMWH may need consideration pending definitive gynecological treatment.
The potential for reproductive toxicity of DOACs in humans, via maternal or paternal exposure, is undefined. Consequently, the DOAC SPCs recommend avoiding them during pregnancy and breastfeeding [8] [9] [10] [11] . Limited data suggest that embryopathy occurs in 2% of women who experience DOAC exposure in pregnancy [97] . ISTH SSC guidance recommendations can be summarized as follows: (i) women of childbearing potential should receive documented counseling prior to the commencement of DOACs; (ii) should pregnancy be desired, the DOAC should be switched to an alternative anticoagulant before conception, with the main options being VKAs (to be switched to LMWH as soon as possible when pregnancy is achieved and before 6 weeks of gestation), or LMWH, with cognizance that the latter may result in prolonged subcutaneous injections until pregnancy is achieved; (iii) in women who become pregnant while receiving a DOAC, the DOAC should be discontinued immediately and LMWH commenced; (iv) inadvertent exposure to a DOAC would not in itself be regarded as medical grounds for termination of pregnancy; (v) in women who become pregnant while receiving a DOAC and who decide to continue with pregnancy, there should be early obstetrical review and fetal monitoring; and (vi) breastfeeding women should not be treated with DOACs [98] . The ISTH SSC guidance on DOACs in women of childbearing potential also recommends that all cases of DOAC exposure during pregnancy should be reported to the international ISTH registry to ensure consistency of data collection: http://www.surveygizmo.com/s3/2394649/International-registry-of-pregnanc y-during-NOAC-use-Inclusion.
Conclusions
The RAPS trial, which had a surrogate laboratory primary outcome measure, suggests that rivaroxaban has the potential to be an effective and convenient alternative to warfarin in thrombotic APS patients with a single VTE event requiring standard-intensity anticoagulation. However, further studies, in particular to provide better longterm efficacy and safety data, are needed before it can be widely recommended. APS DOAC RCTs with clinical primary outcomes represent the gold standard; however, a primary endpoint of recurrent thrombosis would require a larger sample size than has been achieved to date. APS patients are clinically heterogeneous, with the risk of recurrent thrombosis and the intensity of anticoagulation being influenced by their clinical phenotype and risk profile. Thus, DOAC trials involving homogeneous thrombotic APS populations, with aPL status well defined, will help to optimize the appropriate treatment in APS patient subgroups. Ongoing and emerging RCTs should provide further information to guide the use of DOACs in APS patients. Optimal identification of APS patients merits attention, as this is a key step in working towards improved therapeutic strategies in these individuals.
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